Doctors are trialling a new vaccine that could protect children against meningitis B. Until recently there has been no way of preventing this particular strain, which is highly aggressive and can be fatal.
Nearly 2,000 people contract the infection every year - many are babies and young children. The trials are currently taking place in four cities - including Bristol.
Watch Andrew Pate's report and an interview with Chris Head, the Chief Executive of the Thornbury-based Meningitis Research Foundation here:
Every year in the UK around three and a half thousand people contract meningitis. And every week, six families lose a loved one to the disease.
Claire Middleton from Weston-super-Mare nearly lost her baby, Edith, when she was just a few hours old. Now at the start of Meningitis Awareness Week she wants people to learn from her experience. David Woodland reports.
A vaccine that protects against a potentially deadly form of meningitis should not be offered to children in the UK, immunisation experts have said.
The independent panel, which advises the Government on which vaccines should be offered in the UK, released a draft statement saying that the treatment against meningitis B should not be rolled out.
Meningitis B, which is most common in children under five years old, and in particular in babies under the age of one, is a highly aggressive strain of bacterial meningitis. It can cause severe brain damage, septicaemia or even death.
The country's two leading meningitis charities have announced plans to merge. Bristol-based Meningitis UK and the Meningitis Trust in Stroud will join forces next month. They're planning to keep their individual names until a re-launch at the end of the year.
Onor Crummay fell ill with meninigitis B when she was a student at the University of Bristol. It left her with learning difficulties which she managed to battle and now supports Meningitis UK's campaign to get the Government to have children immunised against strain B of bug.
Here is her message about how important a vaccine is.